tbuckley/cabot-search huggingface dataset:
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series
Authors: Nathalie Forgeard, Dikélélé Elessa, Alexander Carpinteiro, Karim Belhadj, Monique Minnema, Murielle Roussel, Antoine Huart, Vincent Javaugue, Laurent Pascal, Bruno Royer, Alexis Talbot, Romain Gounot, Ute Hegenbart, Stefan Schonland, Lionel Karlin, Stéphanie Harel, Efstathios Kastritis, Frank Bridoux, Arnaud Jaccard, Bertrand Arnulf
Journal: Blood (2023)

Teclistamab shows promising results in R/R AL amyloidosis, with VGPR or better in 88% of patients and involved FLC < 10 mg/L in 76%. We observed a 35% rate of severe infections and no cardiac or kidney related events.
Ghrelin deletion and conditional ghrelin cell ablation increase pancreatic islet size in mice
Authors: Deepali Gupta, Avi W. Burstein, Dana C. Schwalbe, Kripa Shankar, Salil Varshney, Omprakash Singh, Subhojit Paul, Sean B. Ogden, Sherri Osborne-Lawrence, Nathan P. Metzger, Corine P. Richard, John N. Campbell, Jeffrey M. Zigman
Journal: Journal of Clinical Investigation (2023)

Ghrelin exerts key effects on islet hormone secretion to regulate blood glucose levels. Here, we sought to determine whether ghrelin's effects on islets extend to the alteration of islet size and β cell mass. We demonstrate that reducing ghrelin - by ghrelin gene knockout (GKO), conditional ghrelin cell ablation, or high-fat diet (HFD) feeding - was associated with increased mean islet size (up to 62%), percentage of large islets (up to 854%), and β cell cross-sectional area (up to 51%). In GKO mice, these effects were more apparent in 10- to 12-week-old mice than in 4-week-old mice. Higher β cell numbers from decreased β cell apoptosis drove the increase in β cell cross-sectional area. Conditional ghrelin cell ablation in adult mice increased the β cell number per islet by 40% within 4 weeks. A negative correlation between islet size and plasma ghrelin in HFD-fed plus chow-fed WT mice, together with even larger islet sizes in HFD-fed GKO mice than in HFD-fed WT mice, suggests that reduced ghrelin was not solely responsible for diet-induced obesity-associated islet enlargement. Single-cell transcriptomics revealed changes in gene expression in several GKO islet cell types, including upregulation of Manf, Dnajc3, and Gnas expression in β cells, which supports decreased β cell apoptosis and/or increased β cell proliferation. These effects of ghrelin reduction on islet morphology might prove useful when designing new therapies for diabetes.
Toward Ablative SBRT for Nonmetastatic PDAC
Journal: Cancer Discovery (2023)

Combining a superoxide dismutase mimetic, avasopasem manganese, with stereotactic body radiation therapy may enable safe delivery of higher than standard radiation doses for patients with nonmetastatic, inoperable pancreatic adenocarcinoma. The phase Ib/II findings also suggest improved outcomes with avasopasem's addition, although the trial wasn't designed to compare arms and a larger study is needed.
Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens
Authors: Michael R. Schlabach, Sharon Lin, Zachary R. Collester, Christopher Wrocklage, Sol Shenker, Conor Calnan, Tianlei Xu, Hugh S. Gannon, Leila J. Williams, Frank Thompson, Paul R. Dunbar, Robert A. LaMothe, Tracy E. Garrett, Nicholas Colletti, Anja F. Hohmann, Noah J. Tubo, Caroline P. Bullock, Isabelle Le Mercier, Katri Sofjan, Jason J. Merkin, Sean Keegan, Gregory V. Kryukov, Caroline Dugopolski, Frank Stegmeier, Karrie Wong, Fiona A. Sharp, Louise Cadzow, Micah J. Benson
Journal: Journal of Clinical Investigation (2023)

Cell therapies such as tumor-infiltrating lymphocyte (TIL) therapy have shown promise in the treatment of patients with refractory solid tumors, with improvement in response rates and durability of responses nevertheless sought. To identify targets capable of enhancing the antitumor activity of T cell therapies, large-scale in vitro and in vivo clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 screens were performed, with the SOCS1 gene identified as a top T cell-enhancing target. In murine CD8+ T cell-therapy models, SOCS1 served as a critical checkpoint in restraining the accumulation of central memory T cells in lymphoid organs as well as intermediate (Texint) and effector (Texeff) exhausted T cell subsets derived from progenitor exhausted T cells (Texprog) in tumors. A comprehensive CRISPR tiling screen of the SOCS1-coding region identified sgRNAs targeting the SH2 domain of SOCS1 as the most potent, with an sgRNA with minimal off-target cut sites used to manufacture KSQ-001, an engineered TIL therapy with SOCS1 inactivated by CRISPR/Cas9. KSQ-001 possessed increased responsiveness to cytokine signals and enhanced in vivo antitumor function in mouse models. These data demonstrate the use of CRISPR/Cas9 screens in the rational design of T cell therapies.
Kidney Disease in Women With Previous Gestational Diabetes Mellitus: A Nationwide Register-Based Cohort Study
Authors: Maria Hornstrup Christensen, Claus Bistrup, Katrine Hass Rubin, Ellen Aagaard Nohr, Christina Anne Vinter, Marianne Skovsager Andersen, Sören Möller, Dorte Moeller Jensen
Journal: Diabetes Care (2023)

OBJECTIVE The association between gestational diabetes mellitus (GDM) and incident kidney disease, the mediating effects of diabetes and hypertension, and the impact of severity of metabolic dysfunction during pregnancy on the risk of incident kidney disease were investigated in this study. RESEARCH DESIGN AND METHODS This Danish, nationwide, register-based cohort study included all women giving birth between 1997 and 2018. Outcomes included chronic kidney disease (CKD) and acute kidney disease, based on diagnosis codes. Cox regression analyses explored the association between GDM and kidney disease. A proxy for severity of metabolic dysfunction during pregnancy was based on GDM diagnosis and insulin treatment during GDM in pregnancy and was included in the models as an interaction term. The mediating effects of subsequent diabetes and hypertension prior to kidney disease were quantified using mediation analyses. RESULTS Data from 697,622 women were used. Median follow-up was 11.9 years. GDM was associated with higher risk of CKD (adjusted hazard ratio [aHR] 1.92; 95% CI 1.67–2.21), whereas acute kidney disease was unrelated to GDM. The proportions of indirect effects of diabetes and hypertension on the association between GDM and CKD were 75.7% (95% CI 61.8–89.6) and 30.3% (95% CI 25.2–35.4), respectively, as assessed by mediation analyses. The CKD risk was significantly increased in women with insulin-treated GDM and no subsequent diabetes compared with women without GDM (aHR 2.35; 95% CI 1.39–3.97). CONCLUSIONS The risk of CKD was significantly elevated after GDM irrespective of subsequent development of diabetes and hypertension. Furthermore, women with severe metabolic dysfunction during pregnancy had the highest CKD risk.
Association of novel adult cough subclasses with clinical characteristics and lung function across six decades of life in a prospective, community-based cohort in Australia: an analysis of the Tasmanian Longitudinal Health Study (TAHS)
Authors: Jingwen Zhang, Caroline J Lodge, E Haydn Walters, Anne B Chang, Dinh S Bui, Adrian J Lowe, Garun S Hamilton, Paul S Thomas, Chamara V Senaratna, Alan L James, Bruce R Thompson, Bircan Erbas, Michael J Abramson, Jennifer L Perret, Shyamali C Dharmage
Journal: The Lancet Respiratory Medicine (2023)
Prevalence of girl and boy child marriage across states and Union Territories in India, 1993–2021: a repeated cross-sectional study
Authors: Jewel Gausman, Rockli Kim, Akhil Kumar, Shamika Ravi, S V Subramanian
Journal: The Lancet Global Health (2023)

India's success in eliminating child marriage is crucial to the achievement of the Sustainable Development Goal target 5.3. We aimed to estimate the prevalence of child marriage in girls and boys in India and describe its change across 36 states and Union Territories between 1993 and 2021.
Stereotactic radiosurgery for nonfunctioning pituitary tumor: A multicenter study of new pituitary hormone deficiency
Authors: Chloe Dumot, Georgios Mantziaris, Sam Dayawansa, Selcuk Peker, Yavuz Samanci, Ahmed M Nabeel, Wael A Reda, Sameh R Tawadros, Khaled Abdelkarim, Amr M N El-Shehaby, Reem M Emad, Ahmed Ragab Abdelsalam, Roman Liscak, Jaromir May, Elad Mashiach, Fernando De Nigris Vasconcellos, Kenneth Bernstein, Douglas Kondziolka, Herwin Speckter, Ruben Mota, Anderson Brito, Shray Kumar Bindal, Ajay Niranjan, Dade L Lunsford, Carolina Gesteira Benjamin, Timoteo Abrantes de Lacerda Almeida, Jennifer Mao, David Mathieu, Jean-Nicolas Tourigny, Manjul Tripathi, Joshua David Palmer, Jennifer Matsui, Joe Crooks, Rodney E Wegner, Matthew J Shepard, Mary Lee Vance, Jason P Sheehan
Journal: Neuro-Oncology (2023)

Abstract Background Stereotactic radiosurgery (SRS) is used to treat recurrent or residual nonfunctioning pituitary neuroendocrine tumors (NFPA). The objective of the study was to assess imaging and development of new pituitary hormone deficiency. Methods Patients treated with single-session SRS for a NFPA were included in this retrospective, multicenter study. Tumor control and new pituitary dysfunction were evaluated using Cox analysis and Kaplan–Meier curves. Results A total of 869 patients (male 476 [54.8%], median age at SRS 52.5 years [Interquartile range (IQR): 18.9]) were treated using a median margin dose of 14Gy (IQR: 4) for a median tumor volume of 3.4 cc (IQR: 4.3). With a median radiological follow-up of 3.7 years (IQR: 4.8), volumetric tumor reduction occurred in 451 patients (51.9%), stability in 364 (41.9%) and 54 patients (6.2%) showed tumor progression. The probability of tumor control was 95.5% (95% Confidence Interval [CI]: 93.8–97.3) and 88.8% (95%CI: 85.2–92.5) at 5 and 10 years, respectively. A margin dose &amp;gt;14 Gy was associated with tumor control (Hazard Ratio [HR]:0.33, 95% CI: 0.18–0.60, P &amp;lt; 0.001). The probability of new hypopituitarism was 9.9% (95% CI: 7.3–12.5) and 15.3% (95% CI: 11–19.4) at 5 and 10 years, respectively. A maximum point dose &amp;gt;10 Gy in the pituitary stalk was associated with new pituitary hormone deficiency (HR: 3.47, 95% CI: 1.95–6.19). The cumulative probability of new cortisol, thyroid, gonadotroph, and growth hormone deficiency was 8% (95% CI: 3.9–11.9), 8.3% (95% CI: 3.9–12.5), 3.5% (95% CI: 1.7–5.2), and 4.7% (95% CI: 1.9–7.4), respectively at 10 years. Conclusions SRS provides long-term tumor control with a 15.3% risk of hypopituitarism at 10 years.
A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience
Authors: John S. Fuqua, Eda Shi, Erica A. Eugster
Journal: International Journal of Transgender Health (2023)

Androgen blockers are an essential part of gender affirming care in post-pubertal transfeminine patients. Bicalutamide is a highly potent androgen receptor blocker that is used primarily in adults. We aimed to review our experience with the use of bicalutamide in transgender adolescents who were assigned male at birth.
Navigating the landscape: Roles, perspectives, and experiences of psychologists supporting gender diverse children and young people in school settings
Authors: Gracie New-Brown, Cora Sargeant, Sarah Wright
Journal: International Journal of Transgender Health (2023)

This review aimed to explore and synthesize the perspectives and experiences of school-based psychological professionals providing support to gender diverse CYP across the world, to foreground the voices of those with relevant experience and support future practice.
Bridges and Mechanisms: Integrating Systems Science Thinking into Implementation Research
Authors: Douglas A. Luke, Byron J. Powell, Alejandra Paniagua-Avila
Journal: Annual Review of Public Health (2023)

We present a detailed argument for how to integrate, or bridge, systems science thinking and methods with implementation science. We start by showing how fundamental systems science principles of structure, dynamics, information, and utility are relevant for implementation science. Then we examine the need for implementation science to develop and apply richer theories of complex systems. This can be accomplished by emphasizing a causal mechanisms approach. Identifying causal mechanisms focuses on the “cogs and gears” of public health, clinical, and organizational interventions. A mechanisms approach focuses on how a specific strategy will produce the implementation outcome. We show how connecting systems science to implementation science opens new opportunities for examining and addressing social determinants of health and conducting equitable and ethical implementation research. Finally, we present case studies illustrating successful applications of systems science within implementation science in community health policy, tobacco control, health care access, and breast cancer screening.
A commentary on ‘Risk factors of epidural hematoma in patients undergoing spinal surgery: a meta-analysis of 29 cohort studies’
Authors: Guohua Luo, Yanqiu Xie
Journal: International Journal of Surgery (2023)

Department of Orthopaedics, People's Hospital of Jingshan, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen City, Hubei Province, China, 431899 This is a comment, no original data in this manuscript. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article Published online ■ ■ *Corresponding author. Address: Department of Orthopaedics, People's Hospital of Jingshan, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen City, Hubei Province, China, 431899. E-mail address: [email protected] (Y. Xie) This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Comments on ‘mapping the landscape of immunonutrition and cancer research: a comprehensive bibliometric analysis on behalf of Nutrionc Research Group’
Authors: Jiawen Wang, Xinhao Wang, Yaoguang Zhang, Jianye Wang
Journal: International Journal of Surgery (2023)

aDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China bGraduate School of Peking Union Medical College, Chinese Academy of Medical Sciences,Beijing 100730, China These authors have contributed equally to this work: Jiawen Wang; Xinhao Wang Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: 1 Dahua Road, Dongdan, Dongcheng District, Beijing Hospital,Beijing,100730,China. E-mail address: [email protected] (J. Wang). This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/
Milestone in infant health: unveiling the RSV vaccine’s shielding effect for newborns
Authors: Zainab Nazir, Ashna Habib, Tooba Ali, Ajeet Singh, Eeshal Zulfiqar, Md Ariful Haque
Journal: International Journal of Surgery (2023)

Nazir, Zainab; Habib, Ashna; Ali, Tooba; Singh, Ajeet; Zulfiqar, Eeshal; Haque, Md Ariful Author Information
The effect of remimazolam on hypotension risk during procedural sedation
Authors: Kuo-Chuan Hung, I-Wen Chen, Ping-Hsin Liu
Journal: International Journal of Surgery (2023)

aDepartment of Anesthesiology, Chi Mei Medical Center, Tainan city, Taiwan bDepartment of Anesthesiology, Chi Mei Medical Center, Liouying, Tainan city, Taiwan cDepartment of Anesthesiology, E-Da Dachang Hospital, I-Shou University, Kaohsiung City, Taiwan Short title: Remimazolam for procedural sedation Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding Author. Address: Ping-Hsin Liu, Department of Anesthesiology, E-Da Dachang Hospital, I-Shou University, No. 305, Dachang 1st Road, Sanmin District, Kaohsiung City, Taiwan. Tel: +886-7-6150011 ext 1007. Fax: +886-7-6150915. E-mail address: [email protected] This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/
Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial
Authors: Mohamed Hany, Bart Torensma, Mohamed Ibrahim, Ahmed Zidan, Ann S.S. Agayby, Mohamed H. Abdelkhalek, Iman El Sayed
Journal: International Journal of Surgery (2023)

Background: Conversional bariatric surgery inherently has less weight loss (WL) compared to primary procedures. Adjunctive use of the GLP-1 analog, liraglutide with conversional Roux-en-Y Gastric Bypass (cRYGB) may maximize the WL benefits of surgery. Material and methods: This single-center randomized double-blind placebo-controlled trial included 80 patients randomized into two groups; the liraglutide group (40 patients) who received daily injections of liraglutide, and the placebo group (40 patients) who received normal saline starting at 6 weeks from cRYGB and continued for 6 months. After discontinuing the drugs at 6 months and unblinding, the patient were followed up to 12 months. The endpoints were percentage of total weight loss (%TWL) and percentage of excess weight loss (%EWL), and changes in the metabolic biomarkers, and complications within 30 and 90 days according to the global outcome benchmark (GOB) stratification. Results: In total, 38 patients in the liraglutide group and 31 in the placebo group completed the 24 weeks. Liraglutide group experienced better WL with a significantly higher mean %TWL at 1 month (10.27±1.39 vs. 8.41±2.08), at 6 weeks (12.65±1.77 vs. 10.47±2.23), at 6 months (18.29 ±1.74 vs. 15.58 ±1.65), and at 12 months 24.15±2.35 versus 22.70±2.13 (all P &lt;0.001). For %EWL, this was also significantly higher in the liraglutide group at all time points. A %TWL of greater than 20% at 6 months of treatment was recorded in six (15.8%) patients in the liraglutide group and none in the placebo group ( P =0.029). Both groups had comparable changes in metabolic biomarkers. Adverse events were recorded in 11 (27.5%) patients in the liraglutide, with no adverse events in the placebo group ( P &lt;0.001). Both groups had Clavien–Dindo scores I and II (5.0 and 2.5%), and GOB values indicated that 90.0 and 97.5% were low-risk patients. Conclusion: Adjunctive use of liraglutide with cRYGB gives significantly higher WL and resolution of associated medical problems.
Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis: a trial sequential analysis
Authors: Kuo-Chuan Hung, I-Wen Chen, Ping-Hsin Liu
Journal: International Journal of Surgery (2023)

aDepartment of Anesthesiology, Chi Mei Medical Center, Tainan city, Taiwan bDepartment of Anesthesiology, Chi Mei Medical Center, Liouying, Tainan city, Taiwan cDepartment of Anesthesiology, E-Da Dachang Hospital, I-Shou University, Kaohsiung City, Taiwan Short title: Aspirin for venous thromboembolism prophylaxis Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Department of Anesthesiology, E-Da Dachang Hospital, I-Shou University No. 305, Dachang 1st Road, Sanmin District, Kaohsiung City, Taiwan. Tel: +886-7-6150011 ext 1007. Fax: +886-7-6150915. E-mail address: [email protected] (P-H. Liu). This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/
Conceptualizing and Measuring Trust, Mistrust, and Distrust: Implications for Advancing Health Equity and Building Trustworthiness
Authors: Jennifer Richmond, Andrew Anderson, Jennifer Cunningham-Erves, Sachiko Ozawa, Consuelo H. Wilkins
Journal: Annual Review of Public Health (2023)

Trust is vital to public confidence in health and science, yet there is no consensus on the most useful way to conceptualize, define, measure, or intervene on trust and its related constructs (e.g., mistrust, distrust, and trustworthiness). In this review, we synthesize literature from this wide-ranging field that has conceptual roots in racism, marginalization, and other forms of oppression. We summarize key definitions and conceptual frameworks and offer guidance to scholars aiming to measure these constructs. We also review how trust-related constructs are associated with health outcomes, describe interventions in this field, and provide recommendations for building trust and institutional trustworthiness and advancing health equity. We ultimately call for future efforts to focus on improving the trustworthiness of public health professionals, scientists, health care providers, and systems instead of aiming to increase trust in these entities as they currently exist and behave.
The Economics of Treatment for Depression
Authors: Chad Stecher, Sara Cloonan, Marisa Elena Domino
Journal: Annual Review of Public Health (2023)

The global prevalence of depression has risen over the past three decades across all socioeconomic groups and geographic regions, with a particularly rapid increase in prevalence among adolescents (aged 12-17 years) in the United States. Depression imposes large health, economic, and societal costs, including reduced life span and quality of life, medical costs, and reduced educational attainment and workplace productivity. A wide range of treatment modalities for depression are available, but socioeconomic disparities in treatment access are driven by treatment costs, lack of culturally tailored options, stigma, and provider shortages, among other barriers. This review highlights the need for comparative research to better understand treatments' relative efficacy, cost-effectiveness, scalability, and potential heterogeneity in efficacy across socioeconomic groups and country and cultural contexts. To address the growing burden of depression, mental health policy could consider reducing restrictions on the supply of providers, implementing digital interventions, reducing stigma, and promoting healthy lifestyles.
Obsessive–Compulsive Disorder in Children and Adolescents
Authors: Jordan T. Stiede, Samuel D. Spencer, Ogechi Onyeka, Katie H. Mangen, Molly J. Church, Wayne K. Goodman, Eric A. Storch
Journal: Annual Review of Clinical Psychology (2023)

Obsessive–compulsive disorder (OCD) in children and adolescents is a neurobehavioral condition that can lead to functional impairment in multiple domains and decreased quality of life. We review the clinical presentation, diagnostic considerations, and common comorbidities of pediatric OCD. An overview of the biological and psychological models of OCD is provided along with a discussion of developmental considerations in youth. We also describe evidence-based treatments for OCD in childhood and adolescence, including cognitive behavioral therapy (CBT) with exposure and response prevention (ERP) and pharmacotherapy. Finally, research evaluating the delivery of CBT in different formats and modalities is discussed, and we conclude with suggestions for future research directions.